Weight Loss & GLP-1s

Metabolism doesn't crash at 40 — but muscle loss, testosterone decline, and lifestyle drift conspire to add roughly 1–2 lbs of fat per year while resting energy expenditure stays nearly flat.

Eliminating refined grains and added sugar from your diet removes the two most potent drivers of blood-glucose volatility — and with them, the reactive hunger that follows every insulin spike.

Tirzepatide produces meaningfully greater and somewhat faster weight loss than semaglutide — full stop. The head-to-head SURMOUNT-5 trial confirms it: −20.2% body weight with tirzepatide versus −13.7% with semaglutide at 72 weeks, a statistically significant gap that holds…

Compounded semaglutide produces real short-term weight loss, but the evidence supporting it is thin, uncontrolled, and nowhere near the standard set by branded Wegovy. If you're weighing options, that gap matters.

Semaglutide is no longer just a weight-loss drug — it is a cardiovascular risk-reduction therapy backed by multiple large outcomes trials. Across a spectrum of patients, from high-risk type 2 diabetes to people with obesity and no diabetes at all, semaglutide consistently cuts…

Compounded semaglutide typically costs $200–$500 per month through telehealth platforms and compounding pharmacies, compared to $1,300–$1,400 monthly for brand-name Wegovy. That 60–85% discount drives most demand, but the price difference obscures significant gaps in quality cont

Research-grade retatrutide costs $250–400 per month from peptide suppliers as of mid-2026, with individual vials priced at $40–120 for 5 mg, $70–200 for 10 mg, and $150–400 for 20–30 mg depending on vendor and bulk-order status. That translates to roughly $0.80–$1.20 per milligra

Tirzepatide vs semaglutide — head-to-head comparison for men. Weight loss results, side effects, cost, and how to find a GLP-1 provider near you.

Ozempic (semaglutide) does not directly damage kidneys, but can cause acute kidney injury in rare cases, primarily through dehydration from gastrointestinal side effects. Clinical trials show potential long-term kidney protective benefits for diabetic patients, though monitoring is essential for those with pre-existing kidney conditions.

Yes, Ozempic (semaglutide) has been associated with an increased risk of acute pancreatitis, though the overall risk remains relatively low. Clinical studies and post-market surveillance have identified pancreatitis as a potential side effect, occurring in approximately 0.2-1% of patients taking GLP-1 receptor agonists.

Current research shows mixed evidence on whether semaglutide causes depression. While some studies suggest a potential link to mood changes in certain individuals, large-scale clinical trials have not established a definitive causal relationship between semaglutide and depression.

Yes, semaglutide can cause headaches as a documented side effect. Clinical trials show headaches occur in 5-14% of patients, typically during the initial weeks of treatment as the body adjusts to the medication.

Tirzepatide does not directly cause hair loss, but rapid weight loss associated with the medication can trigger telogen effluvium, a temporary form of hair shedding that typically occurs 2-4 months after significant weight reduction and usually resolves within 6-9 months.

Current evidence from clinical trials involving over 16,800 patients shows no increased cancer risk from Ozempic in humans. However, the medication carries a black box warning due to thyroid C-cell tumors observed in rodent studies, and it's contraindicated for patients with a personal or family history of medullary thyroid carcinoma.

Semaglutide can be associated with hair loss, though it's not a primary side effect listed in initial clinical trials. The hair loss is typically temporary and linked to rapid weight loss, nutritional deficiencies, and metabolic stress rather than a direct drug effect.

Current evidence suggests Ozempic does not directly cause depression in most patients, though some post-marketing reports have raised concerns. Clinical trials show no significant increased risk, but individual responses vary and mental health monitoring is recommended during treatment.

Yes, Ozempic can cause hair loss in some users. This side effect is primarily linked to rapid weight loss, nutritional deficiencies, and metabolic changes rather than direct drug toxicity, typically occurring 2-6 months after starting treatment.

Yes, Ozempic can cause tiredness in some patients, though fatigue is relatively uncommon, affecting approximately 0.4% to 11% of users. The fatigue is often related to reduced calorie intake, blood sugar changes, or adjustment periods rather than a direct drug effect.

Ozempic (semaglutide) works by mimicking the natural hormone GLP-1, which regulates blood sugar by stimulating insulin release, suppressing glucagon, slowing digestion, and reducing appetite through multiple pathways in the body.

Ozempic (semaglutide) is primarily FDA-approved for treating type 2 diabetes by improving blood sugar control, and it's also used off-label for weight management due to its appetite-suppressing effects.

Ozempic is a prescription-only medication available through licensed pharmacies with a valid prescription from a healthcare provider.

Current scientific evidence does not indicate that semaglutide causes cancer, though ongoing long-term studies continue to monitor safety.

Yes, body aches can occur as a side effect of tirzepatide, particularly during the initial weeks of treatment or dose escalation, though they are generally temporary and mild to moderate in severity.

Yes, diarrhea is a common side effect of Ozempic (semaglutide), affecting approximately 8.5% of patients who take the medication.